)
NEXGEL (NXGL) investor relations material
NEXGEL M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Deal rationale and strategic fit
Acquisition of Celularity's Degenerative Wound segment expands into regenerative medicine, forming the BioNX Surgical division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, bone regeneration, and wound care.
Strategic partnership with Sequence LifeScience enhances manufacturing, development, and commercialization capabilities, leveraging complementary innovation strengths.
Diversifies product portfolio with six established regenerative biomaterial products, over a decade of clinical use, reimbursement pathways, and three planned 510(k) filings over the next three years.
Acquisition brings an experienced commercial and scientific team, expanding internal capabilities and supporting future product development.
Leadership highlights the transformative nature of the deal and alignment with long-term growth and value creation.
Financial terms and conditions
Financing secured through $5.5 million investment from Sequence LifeScience, structured as convertible notes at $0.60 conversion price with 50% warrant coverage at $0.80 strike price.
$5.3 million paid at closing to Celularity; $2.9 million in back commissions to sales reps, some of which is reinvested.
Celularity received a $5 million convertible note, half of which was transferred to Sequence to settle preexisting debt.
Convertible note matures in 18 months with a 10% coupon.
Deal expected to triple annual revenue to approximately $35 million and be immediately accretive to profitability.
Synergies and expected cost savings
Integration of sales force enables commercialization of both acquired and existing products, leveraging established hospital relationships.
Sequence LifeScience will serve as contract and backup manufacturer, assist in new product development, and expand distribution channels.
Collaboration expected to accelerate product development, broaden commercial footprint, and support scalable product expansion.
- Revenue up 31.5% to $11.4M, but net loss of $3.0M and going concern risks persist.NXGL
Q4 202523 Apr 2026 - Hydrogel innovation and strategic partnerships fuel rapid growth and expanding product lines.NXGL
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026 - Record revenue growth and improved margins set stage for positive EBITDA in 2025.NXGL
Q4 202424 Dec 2025 - Shareholders will vote on director elections, incentive plan expansion, and executive pay, all backed by the Board.NXGL
Proxy Filing2 Dec 2025 - Vote to increase authorized common stock to 1B shares for future flexibility is recommended.NXGL
Proxy Filing2 Dec 2025 - Q1 2025 revenue up 121%, margin at 42.4%, and positive EBITDA targeted for 2025.NXGL
Q1 202527 Nov 2025
Next NEXGEL earnings date
Next NEXGEL earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage